Efficacy of Endoscopic Intervention in the Prevention of Portal Genesis Bleedings


Cite item

Abstract

Objective. To analyze the survival of patients with liver cirrhosis and to assess the effectiveness of endoscopic interventions in the prevention of portal genesis bleedings.

Materials and methods. To assess the effectiveness of endoscopic interventions, our study included 449 liver cirrhotic patients with portal hypertension who was admitted with bleeding from varicose veins or the threat of its recurrence for the period from 1996 to 2015. All patients were divided into 2 groups of the study. The main group included 239 patients treated between 2010 and 2015 and the control group consisted of 210 patients in the period from 1996 to 2010.

Results. The analysis showed that the percentage of patients without recurrence of bleeding from varicose veins was 27% (33 patients) in the control group and 54.2% (64) in the main group when performing only endoscopic interventions. With the phased tactics of portosystemic shunt performance after endoscopic interventions this figure amounted to 32.4% (45) and 109 (61.6%). In the structure of mortality of patients without cirrhosis in the long-term period (81 patients) with endoscopic interventions recurrence of bleeding were observed in 40.7% (33) cases in the control group and 68.1% (64 of 94) in the main group. In turn, when combined endoscopy and portosystemic shunting in the structure of the patients, without counting deaths from progressive liver cirrhosis, the proportion of absence of recurrence was 45.9% (in 45 of 98 patients) and 71.2% (in 102 out of 153 tracked in the remote period excluding deaths from cirrhosis). In the group of patients that do not carry out any endoscopic intervention and the patients received only conservative therapy only in 3 (10.7%) cases it was possible to avoid recurrence of bleeding, which determines the therapeutic ineffectiveness isolated attempts to reduce the risk of recurrence of hemorrhagic syndrome.

Conclusion. Modern possibilities of endoscopic technologies have significantly improved the results of treatment and prevention of varicose bleeding or the threat of its recurrence, and the commitment to the phased tactics, with a combination of minimally invasive and traditional decompressive surgery, allowed to increase the survival rates of patients with 80% to 88% - up to 1 year and from 42% to 64% - to 3 years of follow-up.

About the authors

Feruz Gafurovich Nazyrov

Academician V.Vahidova Republican Specialized center of surgery

Author for correspondence.
Email: azam746@mail.ru

MD, Professor, the head of the Department of Surgery of
Portal Hypertension and Pancreatoduodenal Zone, director of the Acad. V.Vahidov Republican Specialized Center of Surgery

Uzbekistan, 10 Farkhad str., 100115, Tashkent, Uzbekistan

Andrey Vasilevich Devyatov

Academician V.Vahidova Republican Specialized center of surgery

Email: azam746@mail.ru

MD, Professor, Chief Scientist of the Department of Surgery of Portal Hypertension and Pancreatoduodenal Zone

Uzbekistan, 10 Farkhad str., 100115, Tashkent, Uzbekistan

Azam Khasanovich Babadjanov

Academician V.Vahidova Republican Specialized center of surgery

Email: azam746@mail.ru

MD, Senior Researcher of the Department of Surgery of Portal Hypertension and Pancreatoduodenal Zone

Uzbekistan, 10 Farkhad str., 100115, Tashkent, Uzbekistan

Djavokhir Azatbaevich Djumaniyazov

Academician V.Vahidova Republican Specialized center of surgery

Email: azam746@mail.ru

endoscopist of department of surgical endoscopy

Uzbekistan, 10 Farkhad str., 100115, Tashkent, Uzbekistan

Renat Ravilevich Baybekov

Academician V.Vahidova Republican Specialized center of surgery

Email: azam746@mail.ru

surgeon of the Department of Surgery of Portal Hypertension and Pancreatoduodenal Zone

Uzbekistan, 10 Farkhad str., 100115, Tashkent, Uzbekistan

References

  1. Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The EndOrgan Impairment in Liver Cirrhosis: Appointments for Critical Care. Critical Care Research and Practice. 2012.
  2. Wiegand J, Berg T: The etiology, diagnosis and prevention of liver cirrhosis-part 1 of a series on liver cirrhosis. Dtsch. Arztebl. Int. 2013; 110: 6: 85–91.
  3. Shertsinger A.G., Zhigalova S.B., Melkumov A.B., Manuk'ian V.G. Varikoznoe rasshirenie ven zheludka u bol'nykh portal'noi gipertenziei: diagnostika i lechenie [Manukyan Varicose veins of the stomach in patients with portal hypertension: diagnosis and treatment] Ann. surgeon. Hepatology. 2010; 84-94. (in Russ.)
  4. Nazyrov F.G., Deviatov A.V., Babadzhanov A.Kh. Svodnyi analiz
  5. rezul'tatov i konkurentnye perspektivy portosistemnogo shuntirovaniia prospects of the competitive portosystemic shunting in patients with cirrhosis of the liver] Ann. surgeon. Hepatology. 2015; 36-41. (in Russ.)
  6. u bol'nykh tsirrozom pecheni [summary analysis of the results and
  7. Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG. Portal vein thrombosis, mortality and hepaticdecompensation in patients with cirrhosis: A meta-analysis. World J Hepatol. 2015; 28; 7(27): 2774-2780.
  8. Garcia-Tsao G., Lim J. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program. American Journal of Gastroenterology. 2009; 104: 7: 1802–1829.
  9. Souk K, Al-Badri M, Azar ST. The Safety and Benefit of Statins in Liver Cirrhosis: a Review. Exp Clin Endocrinol Diabetes. 2015; 123(10): 577-80.
  10. Romcea AA, Tanţău M, Seicean A, Pascu O. The etiology of upper gastrointestinal bleeding in cirrhotic patients. Clujul Med. 2013; 86(1): 21-3.
  11. Nazyrov F.G., Sokolova A.S., Deviatov A.V., Saiapin S.N. Analiz sostoianiia i perspektivy razvitiia transformiruemykh zondov dlia ostanovki krovotechenii iz varikozno-rasshirennykh ven pishchevoda [The analysis of the status and prospects of development of transformable probes to stop bleeding from varicose veins of the esophagus] Surgery 2010; 58-64. (in Russ.)
  12. Williams MJ, Hayes P. Improving the management of gastrointestinal bleeding in patients with cirrhosis. Expert Rev Gastroenterol Hepatol. 2015; 7: 1-11.
  13. Senzolo M, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochatzis E, A Burroughs K.
  14. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012; 32(6): 919-27.
  15. Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, Garcia-Pagán JC, Bosch J; Variceal Bleeding Study Group. Esophageal balloon tamponade Vs esophageal stent in controlling acute refractory variceal bleeding: A multicenter RCT. Hepatology. 2015; 24.
  16. Dzidzava I.I. Otdalennye rezul'taty khirurgicheskoi korrektsii portal'noi gipertenzii i prognosticheskie faktory vyzhivaemosti u bol'nykh tsirrozom pecheni [long-term results of surgical correction of portal hypertension prognostic factors and survival in patients with liver cirrhosis] Abstract. dis. doctor. med. Sciences. SPb. 2010; 48. (in Russ.)
  17. Holster IL, Tjwa ET, Moelker A, Wils A, Hansen BE, Vermeijden JR, Scholten P, van Hoek B, Nicolai JJ, Kuipers EJ, Pattynama PM,
  18. van Buuren HR. Covered TIPS vs endoscopic therapy Β-blocker for
  19. prevention of variceal rebleeding. Hepatology. 2015.

Copyright (c) 2017 Nazyrov F.G., Devyatov A.V., Babadjanov A.K., Djumaniyazov D.A., Baybekov R.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies